InsiderClue
Insiders · Profile

Wapnick Pamela

Chief Financial Officer at Metagenomi Therapeutics. Filing since 5 Sep 2024. CIK 0001995657

Company
Date
Role
Action
Shares
Amount
Of holding
MGX Metagenomi Therapeutics, Inc.
8 Sep 2026
Chief Financial Officer
Sold at will
1,911
$2.21K
0.9%
MGX Metagenomi Therapeutics, Inc.
5 Jun 2026
Chief Financial Officer
Sold at will
2,884
$3.75K
1.4%
MGX Metagenomi Therapeutics, Inc.
5 Mar 2026
Chief Financial Officer
Sold at will
1,581
$2.53K
0.8%
MGX Metagenomi Therapeutics, Inc.
5 Dec 2025
Chief Financial Officer
Sold at will
1,576
$2.79K
0.8%
MGX Metagenomi Therapeutics, Inc.
5 Sep 2025
Chief Financial Officer
Sold at will
1,576
$2.85K
2.2%
MGX Metagenomi Therapeutics, Inc.
6 Jun 2025
Chief Financial Officer
Sold at will
1,576
$2.76K
2.1%
MGX Metagenomi Therapeutics, Inc.
5 Mar 2025
Chief Financial Officer
Sold at will
1,808
$3.39K
2.9%
MGX Metagenomi Therapeutics, Inc.
5 Dec 2024
Chief Financial Officer
Sold at will
1,559
$2.90K
2.5%
MGX Metagenomi Therapeutics, Inc.
5 Sep 2024
Chief Financial Officer
Sold at will
6,265
$18.04K
9.0%
9 decisions on file.